Literature DB >> 6430738

Pituitary response to growth hormone-releasing factor in diabetes. Failure of glucose-mediated suppression.

M Press, W V Tamborlane, M O Thorner, W Vale, J Rivier, J M Gertner, R S Sherwin.   

Abstract

To evaluate the mechanism underlying raised growth hormone levels in diabetes, we compared the response to growth hormone-releasing factor (GRF) in type I diabetic and healthy control subjects. In 12 poorly controlled diabetic subjects (fasting plasma glucose 276 +/- 27 mg/dl) basal serum growth hormone levels were elevated by 200-300% (P less than 0.02), yet the incremental increase in growth hormone after GRF injection was no greater than in control subjects. Furthermore, five additional diabetic subjects with normal growth hormone levels after long-term insulin pump treatment also showed an identical response to GRF. Thus, raised basal growth hormone levels in diabetes and the fall that follows intensive insulin treatment may reflect changes in hypothalamic regulation of, rather than in pituitary responsiveness to, GRF. However, when five normal subjects were restudied during glucose infusion, even quite modest hyperglycemia (plasma glucose approximately 150 mg/dl) caused marked suppression of the response to GRF (P less than 0.005). Thus, the "normal" response to GRF in poorly controlled diabetes is actually inappropriate. Failure of the pituitary to suppress in response to hyperglycemia in diabetes implies a second abnormality that may further aggravate disordered growth hormone secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430738     DOI: 10.2337/diab.33.8.804

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.

Authors:  F Caviezel; G Lepore; M L Maglio; M Croci; G Comi; L Morricone
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

2.  Inappropriate growth-hormone (GH) response to thyrotropin-releasing hormone (TRH) occurs infrequently in well-regulated diabetes mellitus.

Authors:  O Giampietro; M Ferdeghini; R Miccoli; G Gregori; G Penno; S Bertoli; R Navalesi
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

3.  Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus.

Authors:  L R Salgado; M Semer; M Nery; M Knoepfelmacher; A C Lerário; G Póvoa; S Jana; S M Villares; B L Wajchenberg; B Liberman; W Nicolau
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

4.  Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH).

Authors:  G Delitala; P A Tomasi; M Palermo; P Fresu
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

5.  Calcitonin suppresses growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man.

Authors:  A M Lengyel; A L Toledo; M A Czepielewski; J G Vieira; A R Chacra
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

6.  Effect of growth hormone releasing hormone on growth hormone secretion in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Pietschmann; G Schernthaner
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

Review 7.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

8.  Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.

Authors:  A Giustina; C Bodini; S Bossoni; U Valentini; W B Wehrenberg
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

9.  Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV.

Authors:  Esther Merlini; Alessandro Cozzi-Lepri; Antonella Castagna; Andrea Costantini; Sergio Lo Caputo; Stefania Carrara; Eugenia Quiros-Roldan; Maria A Ursitti; Andrea Antinori; Antonella D'Arminio Monforte; Giulia Marchetti
Journal:  BMC Infect Dis       Date:  2021-06-12       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.